First test of new genetic therapy for rare lung disease
Disease control
Ongoing
This is the first human study of an experimental drug called KRRO 110 for Alpha-1 antitrypsin deficiency (AATD), a genetic condition that can cause lung and liver disease. The trial will test single and multiple doses in 64 healthy volunteers and people with AATD to check safety,…
Phase: PHASE1, PHASE2 • Sponsor: Korro Bio, Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC